Vaxcyte (PCVX) total liabilities

Total liabilities · fiscal 2025
$317.21M

Vaxcyte (PCVX) had total liabilities of $317.21M at the end of fiscal 2025 (December 31, 2025). That is 54.4% higher than the $205.50M of fiscal 2024. Figures as of 20 Nov 2026, 00:11 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$317.21M
Change on fiscal 2024
+54.4%
Growth, 5 years
+46.5% a year
Highest on record
$317.21Mfiscal 2025
Lowest on record
$11.76Mfiscal 2019
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Vaxcyte total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 46.5% a year. Across the 7 fiscal years on record (2019–2025), the highest was $317.21M in fiscal 2025 and the lowest $11.76M in fiscal 2019.

History · 7 fiscal years

Total liabilities by fiscal year

Vaxcyte total liabilities, year by year

Vaxcyte (PCVX) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$317.21M 54.4% up
2024$205.50M 22.7% up
2023$167.45M 218.6% up
2022$52.57M 30.4% up
2021$40.32M 14.2% down
2020$46.98M 299.5% up
2019$11.76M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Vaxcyte and comparable companies
CompanyTotal liabilitiesFiscal year
Avantor AVTR$6.23B2025
Ensign Group ENSG$3.23B2025
Vaxcyte PCVX$317.21M2025
Bio-Rad Laboratories BIO$3.12B2025
Molina Healthcare MOH$11.50B2025
Spyre Therapeutics SYRE$62.55M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PCVX

Vaxcyte, figure by figure

Vaxcyte (PCVX) overview: price, valuation and scorecardAll health care companies by market value

Vaxcyte total liabilities: questions and answers

How large are Vaxcyte's total liabilities?

Vaxcyte (PCVX) had total liabilities of $317.21M at the end of fiscal 2025 (December 31, 2025). That is 54.4% higher than the $205.50M of fiscal 2024.

What is the growth rate of Vaxcyte's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 46.5% a year.

What are the highest and lowest total liabilities figures on record for Vaxcyte?

Across the 7 fiscal years on record (2019–2025), the highest was $317.21M in fiscal 2025 and the lowest $11.76M in fiscal 2019.

How is Vaxcyte's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Vaxcyte it is on record here for 7 fiscal years, 2019 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Vaxcyte (PCVX) total liabilities”, data as of 20 November 2026. https://funkfolio.com/stock/PCVX/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.